Nephrogen is a seed-stage biotech company developing curative gene therapies for kidney diseases. Firm's initial indication is autosomal dominant polycystic kidney disease (ADPKD), which affects 600,000 Americans and has no cure or effective treatment. Tolvaptan (JYNARQUE®) is the only FDA approved drug for ADPKD, costs $13K for a 28-day supply, and must be taken twice daily for decades for maximum benefit. Company's solution aims to halt ADPKD from the onset and provide an outright cure for the disease. Nephrogen boldly committed to reimagining therapeutics for life threatening kidney disease. Firm broad patent portfolio will allow us to rapidly translate our technologies into foundational partnerships and transformative treatments.
